Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil

Behavioural Brain Research

Volumn 208, Issue 1, 2010, Pages 112-117

  ElBeltagy, Maha ^a,b   Mustafa, Sarah ^b   Umka, Jariya ^b   Lyons, Laura ^b   Salman, Ahmed ^a   Gloria Tu, Chur Yoe ^b   Bhalla, Nikita ^b   Bennett, Geoffrey ^b   Wigmore, Peter M ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antidepressants; Behaviour; Chemotherapy; Memory; Rat

Indexed keywords

FLUOROURACIL; FLUOXETINE; KI 67 ANTIGEN; SEROTONIN UPTAKE INHIBITOR;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONDITIONED EMOTIONAL RESPONSE TEST; CONDITIONING; CONTROLLED STUDY; DENTATE GYRUS; DRUG MECHANISM; EXPERIMENTAL TEST; HIPPOCAMPUS; IMMOBILIZATION; MALE; MEMORY DISORDER; MITOSIS INHIBITION; NONHUMAN; OBJECT LOCALIZATION RECOGNITION TEST; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; STIMULUS RESPONSE; TASK PERFORMANCE; TREATMENT DURATION; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; CATALEPSY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; EXPLORATORY BEHAVIOR; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FLUOROURACIL; FLUOXETINE; FREEZING REACTION, CATALEPTIC; HIPPOCAMPUS; KI-67 ANTIGEN; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; RATS; SEROTONIN UPTAKE INHIBITORS;

EID: 77951889093     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.11.017     Document Type: Article

References (75)

1. Myers J.S. A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function. Oncol Nurs Forum 2009, 36:E1-10.
2. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha V.B., Compas B.E. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003, 9:967-982.
3. Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009, 18:134-143.
4. Falleti M.G., Sanfilippo A., Maruff P., Weih L., Phillips K.A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005, 59:60-70.
5. Jansen C.E., Miaskowski C., Dodd M., Dowling G., Kramer J. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005, 104:2222-2233.
6. Stewart A., Bielajew C., Collins B., Parkinson M., Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006, 20:76-89.
7. Foley J.J., Raffa R.B., Walker E.A. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) 2008, 199:527-538.
8. Konat G.W., Kraszpulski M., James I., Zhang H.T., Abraham J. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 2008, 23:325-333.
9. Mustafa S., Walker A., Bennett G., Wigmore P.M. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 2008, 28:323-330.
10. Seigers R., Schagen S.B., Beerling W., Boogerd W., Van Tellingen O., Van Dam F.S., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186:168-175.
11. Macleod J.E., Deleo J.A., Hickey W.F., Ahles T.A., Saykin A.J., Bucci D.J. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007, 181:168-172.
12. Winocur G., Vardy J., Binns M.A., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75.
13. Gandal M.J., Ehrlichman R.S., Rudnick N.D., Siegel S.J. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008, 157:95-104.
14. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006, 12:198-205.
15. Blaney S.M., Berg S.L., Boddy A.V. Drug delivery. Brain and Spinal Tumours of Childhood 2004, Hodder Arnold. D.A. Walker, G. Perilongo, G. Punt, R.E. Taylor (Eds.).
16. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
17. Bourke R.S., West C.R., Chheda G., Tower D.B. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973, 33:1735-1746.
18. Kerr I.G., Zimm S., Collins J.M., O'Neill D., Poplack D.G. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984, 44:4929-4932.
19. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Proschel M., Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008, 7:12.
20. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22.
21. Mignone R.G., Weber E.T. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res 2006, 1111:26-29.
22. Kempermann G. Adult Neurogenesis:Stem Cells And Neuronal Developmentin The Adult Brain 2006, Oxford University Press,Oxford, New York.
23. Kitabatake Y., Sailor K.A., Ming G.L., Song H. Adult neurogenesis and hippocampal memory function: new cells, more plasticity, new memories?. Neurosurg Clin N Am 2007, 18:105-113. x.
24. Cassano G.B., Puca F., Scapicchio P.L., Trabucchi M. Paroxetine and Fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002, 63:396-402.
25. Horsfield S.A., Rosse R.B., Tomasino V., Schwartz B.L., Mastropaolo J., Deutsch S.I. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med 2002, 32:337-344.
26. Levkovitz Y., Caftori R., Avital A., Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull 2002, 58:345-350.
27. Mowla A., Mosavinasab M., Pani A. Does Fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007, 27:67-70.
28. Vermetten E., Vythilingam M., Southwick S.M., Charney D.S., Bremner J.D. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003, 54:693-702.
29. Chen H., Pandey G.N., Dwivedi Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 2006, 17:863-867.
30. Marcussen A.B., Flagstad P., Kristjansen P.E., Johansen F.F., Englund U. Increase in neurogenesis and behavioural benefit after chronic Fluoxetine treatment in Wistar rats. Acta Neurol Scand 2008, 117:94-100.
31. Monleon S., Vinader-Caerols C., Arenas M.C., Parra A. Antidepressant drugs and memory: Insights from animal studies. Eur Neuropsychopharmacol 2007.
32. Reagan S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
33. Herrmann R., Reuter J., Port R., Osswald H. Folinic acid effect on 5-fluorouracil kinetics in vivo. J Cancer Res Clin Oncol 1988, 114:87-90.
34. Resstel L.B., Joca S.R., Moreira F.A., Correa F.M., Guimaraes F.S. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 2006, 172:294-298.
35. Yau J.L., Hibberd C., Noble J., Seckl J.R. The effect of chronic Fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res 2002, 106:117-123.
36. Dix S.L., Aggleton J.P. Extending the spontaneous preference test of recognition: evidence of object location and object-context recognition. Behav Brain Res 1999, 99:191-200.
37. Bruel-Jungerman E., Laroche S., Paalme V. New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur J Neurosci 2005, 21:513-521.
38. Paxinos G., Watson C. The Rat Brain In Stereotaxic Coordinates 1997, Academic Press, San Diego, pp 79.
39. Mayhew T.M., Burton G.J. Methodological problems in placental morphometry: apologia for the use of stereology based on sound sampling practice. Placenta 1988, 9:565-581.
40. Mancini M.C., Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab 2006, 50:377-389.
41. Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. Chemobrain' in breast carcinoma?: a prologue. Cancer 2004, 101:466-475.
42. Scherwath A., Mehnert A., Schleimer B., Schirmer L., Fehlauer F., Kreienberg R., et al. Neuropsychological function in high-risk breast cancer survivors after stem cell supported high-dose therapy versus standard dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006, 17:415-423.
43. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Titus-Ernstoff L., et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy or local therapy. J Clin Oncol 2005, 23:4399-4405.
44. Castellon S.A., Silverman D.H., Ganz P.A. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005, 92:199-206.
45. Eichenbaum H., Yonelinas A.P., Ranganath C. The medial temporal lobe and recognition memory. Annu Rev Neurosci 2007, 30:123-152.
46. Rudy J.W., Huff N.C., Matus-Amat P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev 2004, 28:675-685.
47. Rudy J.W., Barrientos R.M., O'Reilly R.C. Hippocampal formation supports conditioning to memory of a context. Behav Neurosci 2002, 116:530-538.
48. Matus-Amat P., Higgins E.A., Barrientos R.M., Rudy J.W. The role of the dorsal hippocampus in the acquisition and retrieval of context memory representations. J Neurosci 2004, 24:2431-2439.
49. Malin E.L., McGaugh J.L. Differential involvement of the hippocampus, anterior cingulate cortex, and basolateral amygdala in memory for context and footshock. Proc Natl Acad Sci U S A 2006, 103:1959-1963.
50. Huff N.C., Rudy J.W. The amygdala modulates hippocampus-dependent context memory formation and stores cue-shock associations. Behav Neurosci 2004, 118:53-62.
51. McGaugh J.L. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci 2004, 27:1-28.
52. Ponnusamy R., Poulos A.M., Fanselow M.S. Amygdala-dependent and amygdala-independent pathways for contextual fear conditioning. Neuroscience 2007, 147:919-927.
53. Mumby D.G., Gaskin S., Glenn M.J., Schramek T.E., Lehmann H. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn Mem 2002, 9:49-57.
54. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or Fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-580.
55. Song L., Che W., Min-Wei W., Murakami Y., Matsumoto K. Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 2006, 83:186-193.
56. Eriksson P.S., Perfilieva E., Bjork-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., et al. Neurogenesis in the adult human hippocampus. Nat Med 1998, 4:1313-1317.
57. Imayoshi I., Sakamoto M., Ohtsuka T., Kageyama R. Continuous neurogenesis in the adult brain. Dev Growth Differ 2009.
58. Jessberger S., Clark R.E., Broadbent N.J., Clemenson G.D., Consiglio A., Lie D.C., et al. Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn Mem 2009, 16:147-154.
59. Zhao C., Deng W., Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell 2008, 132:645-660.
60. Abrous D.N., Koehl M., Le Moal M. Adult neurogenesis: from precursors to network and physiology. Physiol Rev 2005, 85:523-569.
61. Lee K.J., Kim S.J., Kim S.W., Choi S.H., Shin Y.C., Park S.H., et al. Chronic mild stress decreases survival, but not proliferation, of new-born cells in adult rat hippocampus. Exp Mol Med 2006, 38:44-54.
62. Li W.L., Cai H.H., Wang B., Chen L., Zhou Q.G., Luo C.X., et al. Chronic Fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res 2009, 87:112-122.
63. Ramanathan M., Kumar S.N., Suresh B. Evaluation of cognitive function of Fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. Indian J Exp Biol 2003, 41:1269-1272.
64. Stewart C.A., Reid I.C. Repeated ECS and Fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl) 2000, 148:217-223.
65. Holick K.A., Lee D.C., Hen R., Dulawa S.C. Behavioral effects of chronic Fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008, 33:406-417.
66. Cowen D.S., Takase L.F., Fornal C.A., Jacobs B.L. Age-dependent decline in hippocampal neurogenesis is not altered by chronic treatment with Fluoxetine. Brain Res 2008, 1228:14-19.
67. Smith G.S., Reynolds C.F., Houck P.R., Dew M.A., Ma Y., Mulsant B.H., et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 2002, 10:561-567.
68. Saxena S., Brody A.L., Ho M.L., Zohrabi N., Maidment K.M., Baxter L.R. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003, 160:522-532.
69. Brody A.L., Saxena S., Stoessel P., Gillies L.A., Fairbanks L.A., Alborzian S., et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001, 58:631-640.
70. Huang F., Kemp C.J., Williams J.L., Erwin C.R., Warner B.W. Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury. Am J Physiol Gastrointest Liver Physiol 2002, 282:432-442.
71. Mayberg Hs B.S., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of Fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000, 8:830-843.
72. Van Dam F.S., Schagen S.B., Muller M.J., Boogerd W., Vd Wall E., Droogleever Fortuyn M.E., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard dose chemotherapy. J Natl Cancer Inst 1998, 90:210-218.
73. Au J.L., Walker J.S., Rustum Y. Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 1983, 227:174-180.
74. Watson S.A., Michael D., Justin T.A., Grimes S., Morris T.M., Robinson G., Clarke P.A., Hardcastle J.D. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Int J Cancer 1998, 75:873-877.
75. Moser E., Moser M.B., Andersen P. Spatial learning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci 1993, 13:3916-3925.